vs
Side-by-side financial comparison of NATURES SUNSHINE PRODUCTS INC (NATR) and USANA HEALTH SCIENCES INC (USNA), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
USANA HEALTH SCIENCES INC is the larger business by last-quarter revenue ($213.7M vs $123.8M, roughly 1.7× NATURES SUNSHINE PRODUCTS INC). NATURES SUNSHINE PRODUCTS INC runs the higher net margin — 3.3% vs -3.1%, a 6.4% gap on every dollar of revenue. On growth, USANA HEALTH SCIENCES INC posted the faster year-over-year revenue change (6.7% vs 4.7%). NATURES SUNSHINE PRODUCTS INC produced more free cash flow last quarter ($7.6M vs $-5.2M). Over the past eight quarters, NATURES SUNSHINE PRODUCTS INC's revenue compounded faster (5.6% CAGR vs -1.7%).
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
Usana Health Sciences, Inc., or USANA, is an American multi-level marketing company based in Salt Lake City, Utah. As of 2021, Usana was the 14th largest direct-selling company in the world by revenue. The company manufactures most of its nutritional products, dietary supplements, and skincare products at a Salt Lake City facility. Its products are sold in 24 countries via a network of independent distributors.
NATR vs USNA — Head-to-Head
Income Statement — Q4 2025 vs Q3 2026
| Metric | | |
|---|---|---|
| Revenue | $123.8M | $213.7M |
| Net Profit | $4.1M | $-6.5M |
| Gross Margin | 72.5% | 77.2% |
| Operating Margin | 4.3% | 0.6% |
| Net Margin | 3.3% | -3.1% |
| Revenue YoY | 4.7% | 6.7% |
| Net Profit YoY | 1379.4% | -161.5% |
| EPS (diluted) | $0.23 | $-0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align — see 8-quarter trend below.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | $123.8M | — | ||
| Q3 25 | $128.3M | $213.7M | ||
| Q2 25 | $114.8M | $235.8M | ||
| Q1 25 | $113.2M | $249.5M | ||
| Q4 24 | $118.2M | $213.6M | ||
| Q3 24 | $114.6M | $200.2M | ||
| Q2 24 | $110.6M | $212.9M | ||
| Q1 24 | $111.0M | $227.8M |
| Q4 25 | $4.1M | — | ||
| Q3 25 | $5.3M | $-6.5M | ||
| Q2 25 | $5.3M | $9.7M | ||
| Q1 25 | $4.7M | $9.4M | ||
| Q4 24 | $-321.0K | $4.5M | ||
| Q3 24 | $4.3M | $10.6M | ||
| Q2 24 | $1.3M | $10.4M | ||
| Q1 24 | $2.3M | $16.5M |
| Q4 25 | 72.5% | — | ||
| Q3 25 | 73.3% | 77.2% | ||
| Q2 25 | 71.7% | 78.7% | ||
| Q1 25 | 72.1% | 79.0% | ||
| Q4 24 | 72.0% | 82.0% | ||
| Q3 24 | 71.3% | 80.4% | ||
| Q2 24 | 71.4% | 81.1% | ||
| Q1 24 | 71.2% | 81.1% |
| Q4 25 | 4.3% | — | ||
| Q3 25 | 7.0% | 0.6% | ||
| Q2 25 | 3.7% | 7.1% | ||
| Q1 25 | 5.4% | 6.3% | ||
| Q4 24 | 3.8% | 3.8% | ||
| Q3 24 | 4.6% | 7.8% | ||
| Q2 24 | 5.1% | 8.4% | ||
| Q1 24 | 4.2% | 10.8% |
| Q4 25 | 3.3% | — | ||
| Q3 25 | 4.2% | -3.1% | ||
| Q2 25 | 4.6% | 4.1% | ||
| Q1 25 | 4.2% | 3.8% | ||
| Q4 24 | -0.3% | 2.1% | ||
| Q3 24 | 3.8% | 5.3% | ||
| Q2 24 | 1.2% | 4.9% | ||
| Q1 24 | 2.1% | 7.3% |
| Q4 25 | $0.23 | — | ||
| Q3 25 | $0.30 | $-0.36 | ||
| Q2 25 | $0.28 | $0.52 | ||
| Q1 25 | $0.25 | $0.49 | ||
| Q4 24 | $-0.02 | $0.23 | ||
| Q3 24 | $0.23 | $0.56 | ||
| Q2 24 | $0.07 | $0.54 | ||
| Q1 24 | $0.12 | $0.86 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest filing — the kind of financial-strength check premium terminals charge for.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $93.9M | $145.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $161.6M | $528.1M |
| Total Assets | $261.1M | $726.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $93.9M | — | ||
| Q3 25 | $95.6M | $145.3M | ||
| Q2 25 | $81.3M | $151.3M | ||
| Q1 25 | $86.5M | $179.6M | ||
| Q4 24 | $84.7M | $181.8M | ||
| Q3 24 | $78.7M | $364.9M | ||
| Q2 24 | $68.7M | $332.4M | ||
| Q1 24 | $77.8M | $328.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $2.1M | — |
| Q4 25 | $161.6M | — | ||
| Q3 25 | $166.7M | $528.1M | ||
| Q2 25 | $163.7M | $531.1M | ||
| Q1 25 | $167.1M | $529.8M | ||
| Q4 24 | $161.0M | $532.1M | ||
| Q3 24 | $162.6M | $533.1M | ||
| Q2 24 | $156.4M | $512.2M | ||
| Q1 24 | $159.7M | $500.0M |
| Q4 25 | $261.1M | — | ||
| Q3 25 | $264.8M | $726.6M | ||
| Q2 25 | $254.9M | $734.5M | ||
| Q1 25 | $252.7M | $746.6M | ||
| Q4 24 | $240.9M | $748.2M | ||
| Q3 24 | $245.3M | $671.3M | ||
| Q2 24 | $235.8M | $631.4M | ||
| Q1 24 | $247.3M | $629.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.01× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Net income can be massaged; cash flow is harder to fake.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.9M | $-2.0M |
| Free Cash FlowOCF − Capex | $7.6M | $-5.2M |
| FCF MarginFCF / Revenue | 6.1% | -2.4% |
| Capex IntensityCapex / Revenue; lower = less reinvestment burden | 1.9% | 1.5% |
| Cash ConversionOCF / Net Profit; >1× = earnings back up with cash | 2.41× | — |
| TTM Free Cash FlowTrailing 4 quarters | $28.8M | $18.7M |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $9.9M | — | ||
| Q3 25 | $18.5M | $-2.0M | ||
| Q2 25 | $4.3M | $12.2M | ||
| Q1 25 | $2.6M | $15.5M | ||
| Q4 24 | $12.2M | $5.8M | ||
| Q3 24 | $9.6M | $29.5M | ||
| Q2 24 | $1.3M | $8.0M | ||
| Q1 24 | $2.2M | $17.7M |
| Q4 25 | $7.6M | — | ||
| Q3 25 | $16.8M | $-5.2M | ||
| Q2 25 | $3.0M | $7.2M | ||
| Q1 25 | $1.5M | $12.7M | ||
| Q4 24 | $10.0M | $4.0M | ||
| Q3 24 | $7.9M | $27.1M | ||
| Q2 24 | $-2.0M | $5.3M | ||
| Q1 24 | $-1.5M | $14.5M |
| Q4 25 | 6.1% | — | ||
| Q3 25 | 13.1% | -2.4% | ||
| Q2 25 | 2.6% | 3.0% | ||
| Q1 25 | 1.3% | 5.1% | ||
| Q4 24 | 8.5% | 1.9% | ||
| Q3 24 | 6.9% | 13.6% | ||
| Q2 24 | -1.9% | 2.5% | ||
| Q1 24 | -1.4% | 6.4% |
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.3% | 1.5% | ||
| Q2 25 | 1.2% | 2.1% | ||
| Q1 25 | 1.0% | 1.1% | ||
| Q4 24 | 1.9% | 0.8% | ||
| Q3 24 | 1.5% | 1.2% | ||
| Q2 24 | 3.0% | 1.3% | ||
| Q1 24 | 3.3% | 1.4% |
| Q4 25 | 2.41× | — | ||
| Q3 25 | 3.46× | — | ||
| Q2 25 | 0.81× | 1.27× | ||
| Q1 25 | 0.55× | 1.65× | ||
| Q4 24 | — | 1.29× | ||
| Q3 24 | 2.21× | 2.78× | ||
| Q2 24 | 0.97× | 0.77× | ||
| Q1 24 | 0.94× | 1.07× |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
Revenue Breakdown by Segment
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
USNA
| Direct Selling | $175.8M | 82% |
| Hiya | $30.8M | 14% |
| All Other | $7.0M | 3% |
